Answers are grounded in this paper and cite their sources.
This review covers immune and anatomic considerations specific for ovarian cancer immune therapy. Prior approaches and potential reasons for lack of better efficacy are discussed, along with newer approaches in pre-clinical and early clinical development. Potential means for future investigations and means to integrate immune with other approaches are discussed.
No takes yet. Share an insight, caveat, or question.
Thibodeaux et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: